Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

医学 不利影响 肿瘤科 内科学 入射(几何) 乳腺癌 化疗 免疫疗法 癌症 联合疗法 靶向治疗 累积发病率 药理学
作者
Yunwei Lu,Huan Li,Ke Li,Yiting Chen,Shu Wang
出处
期刊:Thoracic Cancer [Wiley]
卷期号:17 (3): e70210-e70210 被引量:2
标识
DOI:10.1111/1759-7714.70210
摘要

Immunotherapy has transformed the therapeutic landscape of breast cancer. Nevertheless, an exhaustive overview of the treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs) spectrum of immune checkpoint inhibitor (ICI)-based combination therapies remains lacking. We performed a comprehensive systematic review and meta-analysis comparing chemotherapy, antibody-drug conjugate (ADC) therapy, targeted therapy, immunotherapy, endocrine therapy, radiotherapy, and dual therapy combined with ICIs. The primary outcomes were overall incidence rates and profiles for all-grade and grade 3 or higher TRAEs and irAEs according to random effects models. We identified 8236 records, 100 of which (9192 patients) met the inclusion criteria. For grade ≥ 3 TRAEs, the ICI-based chemotherapy and ICI-based ADC regimens demonstrated equivalent incidence rates, marginally exceeding those observed in the ICI-based targeted therapy group. Analysis of irAEs revealed that ICI-based chemotherapy combinations had a significantly lower incidence than other dual-agent regimens did. In triplet regimens that combined ICIs with chemotherapy plus additional immunotherapy, irAEs rates remained nearly comparable to those of dual therapies. Among the therapeutic regimens analyzed, ICIs combined with multitarget tyrosine kinase inhibitors (mTKIs) presented the highest incidence rates of both all-grade and grade ≥ 3 irAEs. Conversely, combination regimens of ICIs with poly ADP-ribose polymerase (PARP) inhibitors or HER2-targeted monotherapy demonstrated markedly lower risks of irAEs. Our study provides comprehensive data on the TRAEs and irAEs associated with ICI-based combination therapies. These results offer direct and practical references for clinicians to evaluate toxicity profiles and optimize treatment decisions in routine breast cancer care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
伊莉莎完成签到,获得积分10
刚刚
1秒前
1秒前
英姑的应助被SG采纳,获得30
1秒前
深情安青的应助被学术裁缝采纳,获得10
1秒前
1秒前
无花果的应助被咩了个咩采纳,获得10
2秒前
2秒前
局外人发布了新的文献求助10
2秒前
Juvenilesy的应助被zzt采纳,获得10
2秒前
硼十二完成签到,获得积分10
2秒前
taopaotudou发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
朴素天问发布了新的文献求助30
3秒前
无花果的应助被yifou1110采纳,获得10
3秒前
Maestro_S的应助被echo采纳,获得10
3秒前
7dddd完成签到,获得积分10
3秒前
凡凡发布了新的文献求助10
4秒前
4秒前
zxd1999完成签到,获得积分10
4秒前
hui完成签到,获得积分10
4秒前
内向易文发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
香蕉觅云的应助被Du采纳,获得10
5秒前
Dentrolia完成签到,获得积分20
5秒前
6秒前
搜集达人的应助被1215采纳,获得10
6秒前
6秒前
6秒前
xxxx完成签到,获得积分10
6秒前
6秒前
6秒前
沉默越彬完成签到,获得积分10
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161554
求助须知:如何正确求助?哪些是违规求助? 9556174
关于积分的说明 21732775
捐赠科研通 7751537
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2472023